摘要
弥漫性胶质瘤是成人中最常见的原发性中枢神经系统肿瘤,分为星形细胞瘤、少突胶质细胞瘤和少突星形细胞瘤,病理级别为Ⅱ-Ⅳ级,其中Ⅳ级的胶质母细胞瘤是最常见的高级别胶质瘤。传统上弥漫性胶质瘤的诊断主要是基于其组织病理学特征,但是仍有很多生物学特点无法很好地解释。而以异柠檬酸脱氢酶（IDH）为代表的生物标志物已被证明对脑胶质瘤分子特征的分类和患者预后情况都有不可忽视的作用。IDH在成人Ⅱ级和Ⅲ级弥漫性胶质瘤及继发性胶质母细胞瘤中突变频率较高。IDH突变的浸润性星形细胞瘤和继发性胶质母细胞瘤具有TP53和ATRX突变的特点。少突胶质细胞瘤也伴随IDH突变并以1p/19q联合性缺失和CIC、FUBP1、Notch1、TERT启动子突变为特征。胶质瘤的生物标志物有望成为临床诊断的新标准。
The diffuse gliomas are the most common primary central nervous system tumors in adults.They are subdivided into astrocytomas,oligodendrogliomas and oligoastrocytomas according to histopathologic features and are graded as grades IIIV.Glioblastoma is the highest grade and most frequent astrocytoma.Biomarkers have been demonstrated that they are important to the molecular classification and prediction of therapeutic response of glioma patients.Isocitrate dehydrogenase（ IDH） mutations are frequent in grades II and III diffuse gliomas as well as secondary glioblastoma multiforme,and they are characterized by TP53 and ATRX mutations.The molecular signature of oligodendroglioma includes mutations of IDH,CIC,FUBP1,Notch1 and the TERT promoter together with co-deletion of 1p/19q.As the molecular profiles of gliomas continue to evolve,new guidelines are being proposed to incorporate a tumor ＇s molecular alterations in to the diagnosis.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2016年第1期93-98,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家高技术研究发展计划(863计划)(2012AA02A517)
国家自然科学基金(81173129
81373490)
